Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126993392 | 12699339 | 2 | F | 20160831 | 20160830 | 20160907 | EXP | TW-PFIZER INC-2016405724 | PFIZER | HSIAO, S.. RHABDOMYOLYSIS CAUSED BY THE MODERATE CYP3A4 INHIBITOR FLUCONAZOLE IN A PATIENT ON STABLE ATORVASTATIN THERAPY: A CASE REPORT AND LITERATURE REVIEW. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2016;41(5):575-578 | 70.00 | YR | F | Y | 0.00000 | 20160907 | PH | TW | TW |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126993392 | 12699339 | 1 | PS | FLUCONAZOLE. | FLUCONAZOLE | 1 | Intravenous (not otherwise specified) | 200 MG, DAILY (500 MG LOADING DOSE ) | 19950 | 200 | MG | SOLUTION FOR INFUSION | |||||||
| 126993392 | 12699339 | 2 | I | FLUCONAZOLE. | FLUCONAZOLE | 1 | 19950 | SOLUTION FOR INFUSION | |||||||||||
| 126993392 | 12699339 | 3 | I | FLUCONAZOLE. | FLUCONAZOLE | 1 | 19950 | SOLUTION FOR INFUSION | |||||||||||
| 126993392 | 12699339 | 4 | I | ATORVASTATIN CALCIUM. | ATORVASTATIN CALCIUM | 1 | 20 MG, DAILY | Y | 20702 | 20 | MG | ||||||||
| 126993392 | 12699339 | 5 | I | ATORVASTATIN CALCIUM. | ATORVASTATIN CALCIUM | 1 | 20 MG, ALTERNATE DAY | Y | 20702 | 20 | MG | QOD | |||||||
| 126993392 | 12699339 | 6 | C | PIPERACILLIN/TAZOBACTAM | PIPERACILLIN SODIUMTAZOBACTAM SODIUM | 1 | 2.25 G, EVERY 8 H | 0 | 2.25 | G | TID | ||||||||
| 126993392 | 12699339 | 7 | C | PIPERACILLIN/TAZOBACTAM | PIPERACILLIN SODIUMTAZOBACTAM SODIUM | 1 | 0 | ||||||||||||
| 126993392 | 12699339 | 8 | C | PIPERACILLIN/TAZOBACTAM | PIPERACILLIN SODIUMTAZOBACTAM SODIUM | 1 | 0 | ||||||||||||
| 126993392 | 12699339 | 9 | C | ASPIRIN. | ASPIRIN | 1 | 100 MG, DAILY | 0 | 100 | MG | |||||||||
| 126993392 | 12699339 | 10 | C | BISOPROLOL | BISOPROLOL | 1 | 2.5 MG, DAILY | 0 | 2.5 | MG | |||||||||
| 126993392 | 12699339 | 11 | C | TRAMADOL/ACETAMINOPHEN | ACETAMINOPHENTRAMADOL | 1 | TRAMADOL/ACETAMINOPHEN 37.5/ 325 MG EVERY 6 H | 0 | QID | ||||||||||
| 126993392 | 12699339 | 12 | C | ISOPHANE INSULIN | INSULIN NOS | 1 | 40 IU, 2X/DAY | 0 | 40 | IU | BID | ||||||||
| 126993392 | 12699339 | 13 | C | INSULIN | INSULIN NOS | 1 | 16 IU, 2X/DAY | 0 | 16 | IU | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126993392 | 12699339 | 1 | Candida infection |
| 126993392 | 12699339 | 2 | Urosepsis |
| 126993392 | 12699339 | 3 | Pneumonia |
| 126993392 | 12699339 | 4 | Hyperlipidaemia |
| 126993392 | 12699339 | 6 | Candida infection |
| 126993392 | 12699339 | 7 | Pneumonia |
| 126993392 | 12699339 | 8 | Urosepsis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126993392 | 12699339 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126993392 | 12699339 | Acute kidney injury | |
| 126993392 | 12699339 | Chromaturia | |
| 126993392 | 12699339 | Drug interaction | |
| 126993392 | 12699339 | Muscular weakness | |
| 126993392 | 12699339 | Pain in extremity | |
| 126993392 | 12699339 | Rhabdomyolysis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |